QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=23B9D9F72CA77218F0B6C165F2DFFD4A;jsessionid=97271645C4CD6C1F65A971FDE6CC06CF;jsessionid=4C6710A25D64C726B17E039E5AC9EEC8;jsessionid=9C6A9B8C4B3A93115B8467065BFFEB40;jsessionid=1019B731C1B6E2EA96E18E6CBFCE6F9B;jsessionid=91C2F30CB07C57967527068A6C8A3402 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=E65F5FF2579828E3957F6EC0659BC027;jsessionid=23B9D9F72CA77218F0B6C165F2DFFD4A;jsessionid=97271645C4CD6C1F65A971FDE6CC06CF;jsessionid=4C6710A25D64C726B17E039E5AC9EEC8;jsessionid=9C6A9B8C4B3A93115B8467065BFFEB40;jsessionid=1019B731C1B6E2EA96E18E6CBFCE6F9B;jsessionid=91C2F30CB07C57967527068A6C8A3402